Insulin-like growth factor I, insulin-like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia

Rosebud O Roberts, Debra J. Jacobson, Cynthia J. Girman, Thomas Rhodes, George G. Klee, Michael M. Lieber, Steven J. Jacobsen

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Laboratory studies suggest that insulin-like growth factor I (IGF-I) promotes prostatic growth. The authors evaluated the association between benign prostatic hyperplasia and IGF-I and its binding protein IGFBP-3 in community-dwelling men to determine whether this laboratory finding is manifest at the population level. Participants (n = 471) were Olmsted County, Minnesota, Caucasian males aged 40-79 years in 1990. Urologic measures were assessed from the International Prostate Symptom Score, peak urinary flow rates, prostate volume, and serum prostate-specific antigen (PSA), and serum IGF-I and IGFBP-3 levels were measured. After adjustment for age, the relative odds (odds ratios) of an abnormal urologic measure in men with high versus low serum IGF-I levels were 0.98 (95% confidence interval (Cl): 0.66, 1.45) for a symptom score of >7, 1.14 (95% Cl: 0.72, 1.80) for a peak urinary flow rate of <12 mi/second, 1.11 (95% Cl: 0.72, 1.72) for a prostate volume of <30 mi, and 0.71 (95% Cl: 0.46, 1.09) for a PSA level of <1.4 ng/ml. A low IGFBP-3 level was associated with an enlarged prostate (odds ratio = 1.72, 95% Cl: 1.05, 2.82), after simultaneous adjustment for IGF-I and age, but not with other urologic measures. These data do not provide evidence for an association between benign prostatic hyperplasia and serum IGF-I.

Original languageEnglish (US)
Pages (from-to)784-791
Number of pages8
JournalAmerican Journal of Epidemiology
Volume157
Issue number9
DOIs
StatePublished - May 1 2003

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Prostatic Hyperplasia
Insulin-Like Growth Factor I
Prostate
Odds Ratio
Prostate-Specific Antigen
Serum
Independent Living
Carrier Proteins
Confidence Intervals
Growth
Population

Keywords

  • Insulin-like growth factor binding protein 3
  • Insulin-like growth factor I
  • Men
  • Prostate-specific antigen
  • Prostatic hyperplasia
  • Urological manifestations

ASJC Scopus subject areas

  • Epidemiology

Cite this

Roberts, R. O., Jacobson, D. J., Girman, C. J., Rhodes, T., Klee, G. G., Lieber, M. M., & Jacobsen, S. J. (2003). Insulin-like growth factor I, insulin-like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia. American Journal of Epidemiology, 157(9), 784-791. https://doi.org/10.1093/aje/kwf054

Insulin-like growth factor I, insulin-like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia. / Roberts, Rosebud O; Jacobson, Debra J.; Girman, Cynthia J.; Rhodes, Thomas; Klee, George G.; Lieber, Michael M.; Jacobsen, Steven J.

In: American Journal of Epidemiology, Vol. 157, No. 9, 01.05.2003, p. 784-791.

Research output: Contribution to journalArticle

Roberts, Rosebud O ; Jacobson, Debra J. ; Girman, Cynthia J. ; Rhodes, Thomas ; Klee, George G. ; Lieber, Michael M. ; Jacobsen, Steven J. / Insulin-like growth factor I, insulin-like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia. In: American Journal of Epidemiology. 2003 ; Vol. 157, No. 9. pp. 784-791.
@article{9863e242647c4172b308fa833f95f3b5,
title = "Insulin-like growth factor I, insulin-like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia",
abstract = "Laboratory studies suggest that insulin-like growth factor I (IGF-I) promotes prostatic growth. The authors evaluated the association between benign prostatic hyperplasia and IGF-I and its binding protein IGFBP-3 in community-dwelling men to determine whether this laboratory finding is manifest at the population level. Participants (n = 471) were Olmsted County, Minnesota, Caucasian males aged 40-79 years in 1990. Urologic measures were assessed from the International Prostate Symptom Score, peak urinary flow rates, prostate volume, and serum prostate-specific antigen (PSA), and serum IGF-I and IGFBP-3 levels were measured. After adjustment for age, the relative odds (odds ratios) of an abnormal urologic measure in men with high versus low serum IGF-I levels were 0.98 (95{\%} confidence interval (Cl): 0.66, 1.45) for a symptom score of >7, 1.14 (95{\%} Cl: 0.72, 1.80) for a peak urinary flow rate of <12 mi/second, 1.11 (95{\%} Cl: 0.72, 1.72) for a prostate volume of <30 mi, and 0.71 (95{\%} Cl: 0.46, 1.09) for a PSA level of <1.4 ng/ml. A low IGFBP-3 level was associated with an enlarged prostate (odds ratio = 1.72, 95{\%} Cl: 1.05, 2.82), after simultaneous adjustment for IGF-I and age, but not with other urologic measures. These data do not provide evidence for an association between benign prostatic hyperplasia and serum IGF-I.",
keywords = "Insulin-like growth factor binding protein 3, Insulin-like growth factor I, Men, Prostate-specific antigen, Prostatic hyperplasia, Urological manifestations",
author = "Roberts, {Rosebud O} and Jacobson, {Debra J.} and Girman, {Cynthia J.} and Thomas Rhodes and Klee, {George G.} and Lieber, {Michael M.} and Jacobsen, {Steven J.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1093/aje/kwf054",
language = "English (US)",
volume = "157",
pages = "784--791",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Insulin-like growth factor I, insulin-like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia

AU - Roberts, Rosebud O

AU - Jacobson, Debra J.

AU - Girman, Cynthia J.

AU - Rhodes, Thomas

AU - Klee, George G.

AU - Lieber, Michael M.

AU - Jacobsen, Steven J.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Laboratory studies suggest that insulin-like growth factor I (IGF-I) promotes prostatic growth. The authors evaluated the association between benign prostatic hyperplasia and IGF-I and its binding protein IGFBP-3 in community-dwelling men to determine whether this laboratory finding is manifest at the population level. Participants (n = 471) were Olmsted County, Minnesota, Caucasian males aged 40-79 years in 1990. Urologic measures were assessed from the International Prostate Symptom Score, peak urinary flow rates, prostate volume, and serum prostate-specific antigen (PSA), and serum IGF-I and IGFBP-3 levels were measured. After adjustment for age, the relative odds (odds ratios) of an abnormal urologic measure in men with high versus low serum IGF-I levels were 0.98 (95% confidence interval (Cl): 0.66, 1.45) for a symptom score of >7, 1.14 (95% Cl: 0.72, 1.80) for a peak urinary flow rate of <12 mi/second, 1.11 (95% Cl: 0.72, 1.72) for a prostate volume of <30 mi, and 0.71 (95% Cl: 0.46, 1.09) for a PSA level of <1.4 ng/ml. A low IGFBP-3 level was associated with an enlarged prostate (odds ratio = 1.72, 95% Cl: 1.05, 2.82), after simultaneous adjustment for IGF-I and age, but not with other urologic measures. These data do not provide evidence for an association between benign prostatic hyperplasia and serum IGF-I.

AB - Laboratory studies suggest that insulin-like growth factor I (IGF-I) promotes prostatic growth. The authors evaluated the association between benign prostatic hyperplasia and IGF-I and its binding protein IGFBP-3 in community-dwelling men to determine whether this laboratory finding is manifest at the population level. Participants (n = 471) were Olmsted County, Minnesota, Caucasian males aged 40-79 years in 1990. Urologic measures were assessed from the International Prostate Symptom Score, peak urinary flow rates, prostate volume, and serum prostate-specific antigen (PSA), and serum IGF-I and IGFBP-3 levels were measured. After adjustment for age, the relative odds (odds ratios) of an abnormal urologic measure in men with high versus low serum IGF-I levels were 0.98 (95% confidence interval (Cl): 0.66, 1.45) for a symptom score of >7, 1.14 (95% Cl: 0.72, 1.80) for a peak urinary flow rate of <12 mi/second, 1.11 (95% Cl: 0.72, 1.72) for a prostate volume of <30 mi, and 0.71 (95% Cl: 0.46, 1.09) for a PSA level of <1.4 ng/ml. A low IGFBP-3 level was associated with an enlarged prostate (odds ratio = 1.72, 95% Cl: 1.05, 2.82), after simultaneous adjustment for IGF-I and age, but not with other urologic measures. These data do not provide evidence for an association between benign prostatic hyperplasia and serum IGF-I.

KW - Insulin-like growth factor binding protein 3

KW - Insulin-like growth factor I

KW - Men

KW - Prostate-specific antigen

KW - Prostatic hyperplasia

KW - Urological manifestations

UR - http://www.scopus.com/inward/record.url?scp=0038416674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038416674&partnerID=8YFLogxK

U2 - 10.1093/aje/kwf054

DO - 10.1093/aje/kwf054

M3 - Article

VL - 157

SP - 784

EP - 791

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 9

ER -